Pharvaris BV
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema… Read more
Pharvaris BV (PHVS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.098x
Based on the latest financial reports, Pharvaris BV (PHVS) has a cash flow conversion efficiency ratio of -0.098x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-30.67 Million) by net assets ($312.24 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Pharvaris BV - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Pharvaris BV's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Pharvaris BV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pharvaris BV ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guangzhou Development Group Inc
SHG:600098
|
0.076x |
|
Huaku Development Co Ltd
TW:2548
|
0.539x |
|
Plymouth Industrial REIT Inc
NYSE:PLYM
|
0.036x |
|
Goldsun Building Materials Co Ltd
TW:2504
|
0.053x |
|
Zhejiang Fenglong Electric Co Ltd Class A
SHE:002931
|
0.012x |
|
Porton Fine Chemicals Ltd
SHE:300363
|
0.023x |
|
Cury Construtora e Incorporadora S.A
SA:CURY3
|
0.165x |
|
Hubei TKD Crystal Electn
SHG:603738
|
0.015x |
Annual Cash Flow Conversion Efficiency for Pharvaris BV (2018–2024)
The table below shows the annual cash flow conversion efficiency of Pharvaris BV from 2018 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $267.76 Million | $-120.13 Million | -0.449x | -85.17% |
| 2023-12-31 | $384.05 Million | $-93.05 Million | -0.242x | +46.16% |
| 2022-12-31 | $149.26 Million | $-67.16 Million | -0.450x | -106.78% |
| 2021-12-31 | $204.95 Million | $-44.60 Million | -0.218x | +3.05% |
| 2020-12-31 | $95.79 Million | $-21.50 Million | -0.224x | +37.23% |
| 2019-12-31 | $18.67 Million | $-6.68 Million | -0.358x | +54.81% |
| 2018-12-31 | $4.95 Million | $-3.92 Million | -0.791x | -- |